Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer

Head/Neck

ADU-CL-20 is an open-label, multicenter Phase 2 clinical trial to evaluate the efficacy and safety of intratumoral ADU-S100 (also referred to as MIW815) administered with pembrolizumab in the first-line setting. The population will consist of adults with PD-L1 positive recurrent or metastatic HNSCC.
Head/Neck
II
Gibson, Mike
NCT03937141
VICCHN1976

Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Head/Neck

The objective of this study is to evaluate in a 3 +3 design, the safety of escalating doses of Monalizumab given IV in combination with cetuximab in patients who have received prior systemic regimen(s) for recurrent and / or metastatic squamous cell carcinoma of the head and neck (SCCHN). Cohorts expansion will evaluate antitumor activity of monalizumab and cetuximab with or without anti-PD(L)1
Head/Neck
I/II
Gibson, Mike
NCT02643550
VICCHN18170

Multimodality Therapy before and after Surgery in Patients with Squamous Cell Carcinoma of the Head and Neck

Head/Neck

This phase II clinical trial studies how well multimodality therapy works before and after surgery in patients with squamous cell carcinoma of the head and neck. Immunotherapy with monoclonal antibodies, such as durvalumab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin, nab-paclitaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving carboplatin, nab-paclitaxel, and durvalumab before surgery and using durvalumab with or without radiation therapy and cisplatin after surgery may kill more tumor cells in patients with head and neck cancer.
Head/Neck
II
Gibson, Mike
NCT03174275
VICCHN1890

Patient Perspectives about Discussing Financial Toxicity in Head and Neck Cancer

Head/Neck

Head/Neck
N/A
Langerman, Alexander
VICCSUPP19116

A Phase 1b/2 Study of Duvelisib in Combination with Pembrolizumab in Subjects with Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Multiple Cancer Types

Head/Neck, Phase I
I/II
Gibson, Mike
VICCHNP19109

Construction and Validation of an Oral Health Screening Tool in Head and Neck Cancer Survivors Who Received Chemotherapy or Radiotherapy

Multiple Cancer Types

Head/Neck, Supportive Care
N/A
Smith, Derek
VICCSUPP19107

Cancer Patient Safety Learning Laboratory (CaPSLL): Preventing Clinical Deterioration in Outpatients

Multiple Cancer Types

Head/Neck, Lung
N/A
Weinger, Matthew
VICCMD1998


Head and Neck Tumor Tissue Repository and Clinical Database

Head/Neck

Head/Neck
N/A
Kim, Young Jun
NCT00898638
VICCHN0356

Characterization of Central Pain Syndrome in Survivors of Head and Neck Cancer

Head/Neck

This trial studies the characterization of central pain syndrome in survivors of head and neck cancer. Many head and neck cancer patients have pain after they have completed treatment. Cancer and its treatment may change how the brain manages pain. This can make treatment of post-treatment pain more challenging for health care provides. This trial is being done to better understand how the brain is responding to pain.
Head/Neck
N/A
Lou, Dianne
NCT04128267
VICCHN1982

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: